MANAGEMENT OF PERIPHERAL NEUROPATHY INDUCED BY PACLITAXEL AND NANOPARTICLE ALBUMIN-BOUND PACLITAXEL
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: MIYAJI, Futaba (Kitasato University Hospital, Pharmacy, Sagamihara, Japan)
- Co-author(s): Futaba Miyaji
Peripheral neuropathy is one of the common adverse events with paclitaxel (PTX). Various attempts have been examined to prevent toxicity, however it is not well established. Toxicity management is important to continue chemotherapy.
Retrospective audit was conducted with breast cancer patients who were treated with either tri-weekly nab-PTX (260mg/m.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.